Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • Emergent BioSolutions, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services infectious news

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. U.S. Centers for Disease Control and Prevention, Atlanta, Ga. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical …

    Published on 10/10/2016
  • NewLink, Merck, U.S. Department of Health and Human Services infectious news

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and …

    Published on 10/10/2016
  • Novartis pharmaceuticals news

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Pharmaceuticals Novartis disclosed details of a realignment of resources within the pharmas Novartis Institutes for BioMedical Research (NIBR) that is part …

    Published on 10/10/2016
  • AbbVie, Amgen autoimmune, biosimilars news

    AbbVie Inc. (NASDAQ:ABBV), Chicago, Ill. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Autoimmune, Biosimilars FDA denied a Citizen's Petition from AbbVie requesting that FDA decline to review any IND or …

    Published on 10/3/2016
  • ImmunoGen cancer news

    ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Business: Cancer ImmunoGen will cut headcount by 65 (17%) to about 320 and seek to partner its non-core B cell lymphoma programs IMGN529 and coltuximab ravtansine (SAR3419) …

    Published on 10/3/2016
  • Imprimis pharmaceuticals news

    Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY), San Diego, Calif. Business: Pharmaceuticals Imprimis reduced headcount by 8% and ceased operations at its facility in Texas to streamline operations and move towards …

    Published on 10/3/2016
  • Mast Therapeutics cardiovascular, hematology news

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Business: Cardiovascular, Hematology Mast said it will discontinue clinical development of vepoloxamer (MST-188) and focus on developing aironite (AIR001) to …

    Published on 10/3/2016
  • Novo Nordisk pharmaceuticals news

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Pharmaceuticals Novo Nordisk plans to reduce its workforce by about 1,000 employees to reduce operating costs. Novo has 42,300 positions globally and …

    Published on 10/3/2016
  • Pfizer pharmaceuticals news

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Pharmaceuticals Pfizer said it will not split its innovative and established products businesses into two separate publicly traded companies and will continue to operate …

    Published on 10/3/2016
  • Sanofi, U.S. Department of Health and Human Services infectious news

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) will grant Sanofi …

    Published on 10/3/2016
  • ToolGen genomics news

    ToolGen Inc., Seoul, South Korea Business: Genomics The Korean Intellectual Property Office issued two patents covering ToolGen's CRISPR technology. ToolGen said the patents cover fundamental claims for CRISPR/CRISPR-…

    Published on 10/3/2016
  • Amgen, J&J, Pfizer hematology, biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Hematology, Biosimilars In an appellate brief filed in the U.S. Court …

    Published on 9/26/2016
  • Cytori, U.S. Department of Health and Human Services gene/cell therapy, other news

    Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. U.S. Department of Health and Human Services, Washington, D.C. Business: Gene/Cell therapy, Other HHSs Biomedical Advanced Research and Development Authority (…

    Published on 9/26/2016
  • Medicines Co., Roche, U.S. Department of Health and Human Services infectious news

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research …

    Published on 9/26/2016
  • Merck, Sanofi endocrine/metabolic news

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Sanofi filed a suit in the U.S. District Court for the District of Delaware alleging that Merck …

    Published on 9/26/2016
  • The Chan Zuckerberg Initiative other news

    The Chan Zuckerberg Initiative Business: Other The Chan Zuckerberg Initiative said it will invest more than $3 billion over 10 years in an effort to cure, manage or prevent all diseases by the end of the century. …

    Published on 9/26/2016
  • Bayer, Monsanto agbio/environmental news

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Monsanto Co. (NYSE:MON), St. Louis, Mo. Business: Agbio/Environmental Bayer will acquire Monsanto for $128 per share in cash. The companies said the deal values Monsantos …

    Published on 9/19/2016
  • Catalyst Biosciences hematology news

    Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Business: Hematology Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB …

    Published on 9/19/2016
  • Lundbeck neurology, generics news

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology, Generics The EU General Court upheld a decision from the European Commission to fine Lundbeck for anticompetitive activity related to Lundbecks …

    Published on 9/19/2016
  • Rigel autoimmune news

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Business: Autoimmune Rigel is reducing headcount by 46 (38%) to about 75 to focus on the launch of fostamatinib. The cuts will mostly come from the …

    Published on 9/19/2016
  • Amgen, Apotex hematology, biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Apotex Inc., Toronto, Ontario Business: Hematology, Biosimilars A federal judge in the U.S. District Court for the Southern District of Florida ruled that two biosimilars …

    Published on 9/12/2016
  • Moderna Therapeutics, U.S. Department of Health and Human Services infectious news

    Moderna Therapeutics Inc., Cambridge, Mass. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) granted Moderna a …

    Published on 9/12/2016
  • Takeda, U.S. Department of Health and Human Services infectious news

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded …

    Published on 9/12/2016
  • Cerulean cancer news

    Cerulean Pharma Inc. (NASDAQ:CERU), Waltham, Mass. Business: Cancer Cerulean will reduce headcount by 21 (48%) to 23 after lead candidate CRLX101 missed the primary endpoint in a Phase II trial to treat metastatic renal…

    Published on 9/5/2016
  • Chembio, U.S. Department of Health and Human Services diagnostic news

    Chembio Diagnostics Inc. (NASDAQ:CEMI), Medford, N.Y. U.S. Department of Health and Human Services, Washington, D.C. Business: Diagnostic HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded …

    Published on 9/5/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993